Additionally, Citizens JMP analysts expressed confidence in BioCryst's financial prospects, projecting 2025 revenues between $540 million and $560 million. They also anticipate the Inflation Reduction Act will positively impact ORLADEYO's affordability for Medicare patients, potentially increasing patient retention. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.